The U.S. digital therapeutics market size was estimated at USD 1.60 billion in 2023 and is expected to hit USD 10.01 billion by 2032, registering a compound annual growth rate (CAGR) of 22.6% from 2023 to 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
Digital Therapeutics are proven therapeutic procedures driven by software to prevent, manage or treat a medical condition or disease. In other words, Digital Therapeutics are patient-facing application software that helps in treating, preventing, or managing diseases and have been proved the clinical benefit. For instance, DTx assists the patient in self-managing symptoms and improving their quality of life and other clinical objectives. DTx uses digital tools such as mobile devices, apps, sensors, virtual reality, the Internet of Things, and others in order to induce behavioral changes in patients. DTx development has a positive impact on offering well-adapted health services as their design is targeted to the demands of the patient.
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 22.6% |
| Market Size in 2023 | USD 1.60 Billion |
| Market Size by 2032 | USD 10.01 Billion |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered |
|
Drivers
Rising demand for digital therapeutics
The demand for U.S. digital therapeutics is on the rise owing to increased penetration of digital healthcare applications and platforms due to the rapid adoption of smartphones, tablets, and smart wearables is likely to drive market growth in the coming years. The Rising prevalence of chronic diseases with the growing need to control the rising cost of healthcare facilities is another factor that is expected to drive the market growth. Furthermore, constantly changing digital platforms in many industries have encouraged consumers to use these digital platforms. Also, increased awareness about health and fitness are the major drivers that boost the market in the upcoming years.
Restrains
Data privacy concerns
The various health applications lack the necessary authorization raising issues about the product and data quality, patient privacy, security, and data use responsibly. Digital therapeutics providers have access to the patient’s information but are not permitted to share information about who is involved in the patient’s treatment. However, with the digital technologies to consolidate data, the patient’s information is at risk which can be accessed by any healthcare professional who is not involved in patients’ treatment procedure. As a result, data privacy issues are impeding the growth of the market during the forecast period.
Opportunities
Rising investments and strategic acquisition
Increased pharma investment and healthcare-focused start-ups are more likely to act as market drivers for digital therapeutics, influencing and shaping the future of digital therapeutics. There is also a positive trend for digital medication reimbursement, with 25% of organizations currently covering them and another 45% promising to do so in the future. Consolidation in the digital therapeutics sector is ongoing, with vendors expanding their market presence through strategic acquisitions and collaborations with pharmaceutical companies. Mergers and acquisitions are being used by global and prominent regional suppliers to enhance their market positions and extend their product ranges.
Furthermore, the growing emphasis on strategic acquisitions and the formation of collaborative partnerships among key stakeholders such as providers, payers, and the US federal government to meet prevalent unmet patient needs and provide supportive healthcare services in remote locations is contributing to the growth of the digital therapeutics market in the US. These strategic alliances will boost healthcare infrastructure utilization, enhance patient and physician interaction, and deliver improved disease management and patient access services.
COVID-19 Impact
Following the outbreak of the COVID-19 pandemic, the use of DTx applications in a variety of industries increased significantly. DTx offers one-of-a-kind solutions to meet healthcare needs, lowering the risk of COVID-19 exposure during a hospital visit. The COVID-19 pandemic joined other main drivers of DTx growth, including a greater emphasis on preventative healthcare, a high prevalence of chronic diseases, and more cheap devices as a result of technological advancements. DTx became a significant participant in the digital health sector after COVID, and its scope is anticipated to raise the US digital therapeutics market.
Based on application, the U.S Digital Therapeutics Market is segmented into Diabetes, Obesity, Central Nervous System (CNS), cardiovascular disease (CVD), Gastrointestinal Disorder (GID), Respiratory diseases, Smoking Cessation, and Others). The diabetes segment holds the largest market share during the forecast period owing to the high prevalence of diabetes. Additionally, the demand for cost-efficient healthcare options and high prevalence rates for diabetes are observed in the U.S. thus it further boosts the demand for digital therapeutics among diabetes patients in the country. Moreover, the obesity segment is estimated to account for the highest growth during the forecast period. This is due to the increasing number of overweight populations which leads to an increase in the number of chronic diseases from obesity. Furthermore, improved accessibility of digital therapeutics software applications that assist patients in maintaining a healthy diet, tracking health data, and daily physical activity boosts growth in the US digital therapeutics market. Moreover, the DTx software application offers frequent online guidance from certified doctors, which is projected to contribute to the future reduction of obesity prevalence.
Based on product, the U.S. digital therapeutics market is segmented into software and devices. The software segment is estimated to hold the largest market share during the forecast period. This is due to the rise in demand for the reduction of healthcare costs globally. This would provide immense opportunities to developers to use existing software and also develop new and advanced features to make them more effective and affordable. This is estimated to help propel the U.S. digital therapeutics market size.
Based on End Use, the U.S. digital therapeutics market is segmented into patients, providers, payers, employers, and others. The patient segment dominated the market growth with more than 32% of the revenue share in 2022. The rising adoption of these technologies are linked to their additional advantages, one of which is effective health management at a low cost. Furthermore, the presence of advanced healthcare information systems and supportive federal programs in the country are factors that are predicted to increase patient adoption of digital therapies.
The employer segment is anticipated to grow during the forecast period owing to employers focus on employee healthcare cost control, which is estimated to boost the growth of the segment. Furthermore, increased awareness through employee healthcare programs is projected to drive the use of digital therapies for employee well-being. Availability of multiple mHealth apps like Vida Health, used by payers, providers, and employers to monitor chronic situations such as prediabetes, obesity, hypertension, and mental health disorder are the factors that are expected to drive the market.
Segments Covered in the Report
By Application
By Product
By End Use
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
